THR 0921

Drug Profile

THR 0921

Alternative Names: CLX-0921; THR0921

Latest Information Update: 18 Sep 2015

Price : $50

At a glance

  • Originator Calyx Therapeutics (CEASED)
  • Developer Egret Pharma; Theracos
  • Class Antihyperglycaemics; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Type 2 diabetes mellitus
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 18 Sep 2015 No recent reports on development identified - Clinical-Phase-Unknown for Type-2 diabetes mellitus in China (PO)
  • 18 Sep 2015 No recent reports on development identified - Phase-I/II for Type-2 diabetes mellitus in Europe (PO)
  • 25 Oct 2005 Discontinued - Preclinical for Rheumatoid arthritis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top